Abstract PO1-04-01: Phase 1 Dose Escalation Study of ARX788, a Next-Generation Anti-Her2 Antibody Drug Conjugate, in Heavily Pretreated Breast Cancer Patients
Cancer Research（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined